News

Maze Theory shares held by Calculus Capital EIS Funds and the Calculus VCT plc have been purchased by a strategic investor, Pluto Digital

The essence of eConsult is to ask the questions ahead of the consultation. We gather information 24 hours a day, at the patient’s convenience

Important note: Performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Co-head of investments Richard Moore recently spoke to Wealth Club about Calculus and our VCT offering.

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. By Oliver Warren, Investor Relations Associate In the 21/22 tax year, £1.13bn was invested in VCTs*, a record amount and a more than impressive show of … Continued

The story behind Wonderhood’s new documentary featured in The Telegraph. He is known as the ‘Devil’s Advocate’, and rarely can there have been a more deliciously appropriate epithet. In a legal career that seemingly knew no bounds, Giovanni di Stefano claimed to have offered counsel to Osama bin Laden, Saddam Hussein, Slobodan Milošević, Arkan, Robert … Continued

Arecor’s AT247 has the opportunity to revolutionise diabetic management through creating in effect an artificial pancreas through a closed loop system Over 500 million people suffer with diabetes worldwide and AT247 has the potential to make both management easier and improve average blood glucose levels Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to … Continued

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Welcome to our final quarterly update of 2021. This has been a record-breaking year for Calculus as we have delivered 11 exits and over £50million back to … Continued

By Matthew Moynes, Assistant Director of Investor Relations, Calculus Capital Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Synonymous with UK venture capital investing is the attractive tax incentives provided by  HMRC which help … Continued

UK-based technology company Hinterview has today announced that it has raised £3m in Series A funding. The award-winning video platform for the recruitment sector has experienced soaring demand for their technology, with growth continuing this year as the recruitment industry bounces back in a new era of hybrid-first working. This Series A round, led by … Continued

First patient dosed in SCIB1 Phase 2 clinical trial Trial to assess whether the addition of SCIB1 to pembrolizumab (Keytruda®) will result in an improvement in the tumour response rate and overall survival in patients with advanced melanoma Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious … Continued

Accuracies of 92% and 88% in detection of severe thermal burn injury in adults and children, respectively Article published in Journal of Burn Care and Research on histological burn depth research LONDON, U.K. AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for … Continued

Blu Wireless have been showcasing their new 360° Tactical Vehicle Node, which enables scalable tactical connectivity between vehicles. In contrast to commercial networks, tactical 5G military networks necessitate systems which are standalone, secure, can be easily interfaced to existing tactical equipment and are resistant to single point of failure. Blu Wireless is a firm that … Continued

Interview with Richard Moore – Co Head of Investments – Calculus Capital Calculus Capital has over 20 years’ experience investing in UK growth companies. Calculus works in partnership with investee companies, usually taking a seat on the board and providing advice on a strategic level – with the aim of realising the full potential of … Continued

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus portfolio company, CloudTrade, has been acquired by Advanced, a leading provider of business software, delivering a 4x return to Calculus investors in just over 3 … Continued

Created by Calculus portfolio company Wonderhood Studios, the advert, “Set yourself free”, launches Starling’s new brand platform “Here to change”. It debuts on Channel 4 and Sky channels, with airings during shows including Gogglebox. Wonderhood’s first campaign for Starling Bank, aimed at new businesses, aired in February 2020.

Essentia’s software uses data analytics and behavioural finance research to help allocators and active asset managers make better decisions and improve their returns. Essentia expects to expand headcount and accelerate research and development following an investment by Northern Trust. Northern Trust (Nasdaq: NTRS) has reached an agreement to take an equity stake in Essentia Analytics, Ltd., … Continued

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s … Continued

Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices. Potential to enable more effective disease management for insulin … Continued

Calculus is delighted to announce the appointments of Matthew Moynes and Frank Spurway as Investor Relations Assistant Director and Analyst respectively. Matthew joins Calculus from Barclays Wealth where he was the Head of Venture Capital Products responsible for managing the tax efficient third-party manager panel and driving distribution through product specialist support to Wealth Managers … Continued

Hardman & Co’s latest EIS Navigator Podcast Episode, hosted by Dr Brian Moretta FFA, featured Calculus Capital CEO John Glencross on the topic of “long term perspective on EIS and VCT investing”. You can listen below.

Brouhaha Entertainment was founded by experienced producers: Oscar nominated Gabrielle Tana, Independent film industry pioneer Troy Lum and producer Andrew Mason Founders have successfully produced 27 films and 9 television projects to date, featuring top talent from around the globe Investment will be used to expand the team and fund development in film and particularly … Continued

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus successfully exit Mologic by sale to new philanthropic entity Global Access Health London 19 July 2021: Calculus Capital (“Calculus”), pioneers of the tax efficient investment … Continued

The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 12.30pm on 8 July 2021. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as well as enabling shareholders … Continued

Calculus VCT has invested £0.5m into Spectral MD through an oversubscribed inital public offering onto AIM, on Tuesday 22 June. The Dallas-based firm, which is building notable presence in the UK as part of its product launch effort, produces predictive analytics, proprietary AI algorithms and imaging systems to assist with medical treatment. Spectral MD’s technology, … Continued